Testing for HIV drug resistance prior to initiation of ART has been found to be cost effective in high-resource communities and is recommended by advisory panels, but due to costs is not used in resource-limited communities. The prevalence of transmitted HIV drug resistance has increased in Kenya during the past ten years. We hypothesized that a relatively simple and inexpensive point mutation assay could identify HIV drug resistance in individuals qualifying for 1st-line ART in Kenya, and that use of the test results to choose the ART regimen would improve virologic suppression after 12 months of treatment.
A randomized clinical trial tested Kenyans qualifying for 1st-line ART using a quantitative oligonucleotide ligation assay (OLA). Each subject randomized to OLA was tested at codons 103, 181, 184 and 190 in pol reverse transcriptase to detect and quantify mutations as <10% (not resistant) or ≥10% (resistant) within their quasispecies. Subjects randomized to receive pre-ART OLA with ≥1 resistance mutations were given 2nd-line ART with lopinavir/rt, whereas each individual randomized to “no OLA” received standard of care (SOC) non-nucleoside reverse transcriptase based ART. Plasma HIV RNA was measured pre-ART, at 12 months of ART, and if >40c/mL, again at 15 months.
OLA was implemented at Coptic Hope Center in Nairobi. A total of 991 subjects enrolled into the study in 2013/14. The overall prevalence of resistance was 8.3%. The 12-month study was completed in November 2015.
(Insert Table here)
Testing for HIV drug resistance using a relatively simple and inexpensive point mutation OLA was feasible in Kenya. The OLA testing and initiation of 2nd-line lopinavir/rt-based ART did not significantly impact the overall rate of virologic suppression (1o outcome). Among individuals with resistance detected, rates of virologic suppression were improved by pre-ART OLA testing (2o outcome).
OLA testing for resistance did not improve rates of ART suppression at the population level. Because OLA testing improved outcomes of those with resistance, this study suggests that virologic failure was principally due to other factors. If rates of transmitted resistance continue to increase to increase in Kenya, OLA testing may positively affect overall rates of HIV suppression, and currently, identifying individuals with resistance and starting them on 2nd-line lopinavir/rt-based ART may reduce transmission of drug resistance.